KA-3004

KA-3004: sourced facts only. name: "KA-3004 binds to PD-L1 with high affinity, blocking the interaction of PD-1 and PD-L1." [DOI:10.1158/1538-7445.am2024-2380]; target: "KA-3004 binds to PD-L1 with high affinity, blocking the interaction of PD-1 and PD-L1." [DOI:10.1158/1538-7445.am2024-2380]; developer: "1Kyinno Biotechnology Co., Ltd, Beijing, China." [DOI:10.1158/1538-7445.am2024-2380]; modality: "In this study, we developed a bispecific antibody (BsAb) named KA-3004, targeting PD-L1 and human 4-1BB, with the aim of enhancing the functionality and survival of stimulated CD8+ T cells in the tumor microenvironment." [DOI:10.1158/1538-7445.am2024-2380]; stage: "In PBMC humanized immunodeficient mouse tumor models, KA-3004 effectively suppresses the growth of NCI-H292 tumors expressing PD-L1." [DOI:10.1158/1538-7445.am2024-2380]